EMZAHH
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EMZAHH (EMZAHH).
EMZAHH is a monoclonal antibody that targets and binds to the human epidermal growth factor receptor 2 (HER2), inhibiting downstream signaling pathways involved in cell proliferation and survival.
| Metabolism | Metabolized via catabolic pathways into small peptides and amino acids; not metabolized by CYP450 enzymes. |
| Excretion | Renal 40% unchanged, fecal 50% as metabolites, biliary 10% |
| Half-life | Terminal elimination half-life 12 hours, requiring twice-daily dosing for steady state |
| Protein binding | 98% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 0.5 L/kg, indicating moderate tissue distribution |
| Bioavailability | Oral: 60% (first-pass metabolism), IM: 90% |
| Onset of Action | Oral: 30 minutes; IV: 5 minutes |
| Duration of Action | Oral: 8-12 hours; IV: 6-8 hours, dose-dependent |
10 mg orally twice daily without regard to meals.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR >=30 mL/min. For GFR <30 mL/min, reduce dose to 5 mg twice daily. Not recommended in ESRD (GFR <15 mL/min) or on dialysis. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to 5 mg twice daily. Child-Pugh Class C: Not recommended. |
| Pediatric use | Weight-based dosing: 0.2 mg/kg orally twice daily; maximum 10 mg per dose. Not approved for children <2 years. |
| Geriatric use | Start at 5 mg twice daily; titrate based on tolerability. Increased risk of falls and electrolyte disturbances; monitor renal function and serum potassium. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EMZAHH (EMZAHH).
| Breastfeeding | No data on presence in human milk. Based on molecular weight (400-500 Da) and protein binding (80%), likely excreted. M/P ratio unknown. Breastfeeding not recommended during therapy and for 5 days after last dose. |
| Teratogenic Risk | No human data available. In animal studies, no teratogenic effects observed at exposures up to 10 times the human AUC. However, insufficient data to rule out risk. Avoid use during pregnancy unless clearly needed. |
| Fetal Monitoring |
■ FDA Black Box Warning
Risk of cardiomyopathy: EMZAHH can cause left ventricular dysfunction and heart failure. Risk of infusion reactions: severe and fatal infusion reactions have been reported.
| Serious Effects |
Absolute: None. Relative: Pre-existing congestive heart failure, uncontrolled arrhythmias, or known hypersensitivity to the drug.
| Precautions | Monitor cardiac function before and during treatment. Discontinue if significant left ventricular dysfunction occurs. Monitor for infusion reactions and have resuscitation equipment available. |
| Food/Dietary | No specific food interactions. Avoid excessive alcohol consumption as it may increase bleeding risk. |
Loading safety data…
| Monitor liver function tests (ALT, AST) monthly; complete blood count with differential every 2 weeks during first 3 months, then monthly; serum creatinine and urinalysis for proteinuria every month; fetal ultrasound if exposure occurs in second or third trimester. |
| Fertility Effects | No formal fertility studies in humans. In animal studies, no impairment of male or female fertility observed at clinically relevant doses. Theoretical risk due to hormonal or cytotoxic effects unknown. |
| Clinical Pearls |
| EMZAHH is a novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation. Unlike warfarin, it does not require routine INR monitoring, but renal function must be assessed prior to initiation and periodically thereafter. Avoid use in patients with mechanical heart valves or moderate-to-severe mitral stenosis. Reversal agent (andexanet alfa) is available for life-threatening bleeding. Dose adjustment is required for CrCl 15-29 mL/min; contraindicated if CrCl <15 mL/min or on dialysis. Drug interactions: strong inhibitors of P-glycoprotein (e.g., ketoconazole, ritonavir) increase exposure; avoid concurrent use. |
| Patient Advice | Take this medication exactly as prescribed, at the same time each day with or without food. · Do not stop taking this medicine without talking to your doctor, as this may increase your risk of stroke. · Bleeding is a potential side effect; seek immediate medical help for unusual bleeding, bruising, or blood in urine/stool. · Tell your doctor or dentist that you are taking EMZAHH before any surgery or dental procedure. · If you miss a dose, take it as soon as possible on the same day; do not take double the dose to make up. · Avoid aspirin, NSAIDs (e.g., ibuprofen, naproxen), and other blood thinners unless prescribed by your doctor. |